Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 5:06 PM
Ignite Modification Date:
2025-12-25 @ 2:45 PM
NCT ID:
NCT02345850
Group ID:
EG000
Title:
CD34 Selected Graft
Description:
Mobilized CD34-selected Peripheral Blood Stem Cell graft
Following screening and enrollment, the donor of patients randomized to the CD34-selection arm will receive mobilization therapy with once daily Granulocyte Colony Stimulating Factor (G-CSF). Mobilization will begin on Day -5 prior to the patient's transplant date.
Leukapheresis will be performed on a continuous flow cell separator according to institutional standards and will commence on the morning of the fifth day of G-CSF treatment. The anti-coagulant used for the procedure will be acid citrate dextrose (ACD).
Decisions concerning the need for further product collection will be based on the known or projected enriched CD34+ cell content of the previously collected products.
Mobilized CD34-selected Peripheral Blood Stem Cell graft: Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
Deaths Number Affected:
42
Deaths Number At Risk:
None
Serious Number Affected:
9
Serious Number At Risk:
114
Other Number Affected:
3
Other Number At Risk:
114
Study:
NCT02345850
Results Section:
NCT02345850
Adverse Events Module:
NCT02345850